148 related articles for article (PubMed ID: 36067342)
1. The clinical and economic benefits associated with novel multi-cancer early detection tests: conference highlights from the 2022 ISPOR Annual Meeting.
Nabavizadeh N
Am J Manag Care; 2022 Aug; 28(7 Suppl):S123-S132. PubMed ID: 36067342
[TBL] [Abstract][Full Text] [Related]
2. Examining developments in multicancer early detection: highlights of new clinical data from recent conferences.
Beer TM
Am J Manag Care; 2021 Dec; 27(19 Suppl):S347-S355. PubMed ID: 34870399
[TBL] [Abstract][Full Text] [Related]
3. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
Hackshaw A; Cohen SS; Reichert H; Kansal AR; Chung KC; Ofman JJ
Br J Cancer; 2021 Nov; 125(10):1432-1442. PubMed ID: 34426664
[TBL] [Abstract][Full Text] [Related]
4. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain.
Schmeising-Barnes N; Waller J; Marlow LAV
Soc Sci Med; 2024 Apr; 347():116762. PubMed ID: 38520825
[TBL] [Abstract][Full Text] [Related]
5. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
6. The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
Tafazzoli A; Ramsey SD; Shaul A; Chavan A; Ye W; Kansal AR; Ofman J; Fendrick AM
Pharmacoeconomics; 2022 Nov; 40(11):1107-1117. PubMed ID: 36038710
[TBL] [Abstract][Full Text] [Related]
7. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.
Minasian LM; Pinsky P; Katki HA; Dickherber T; Han PKJ; Harris L; Patriotis C; Srivastava S; Weil CJ; Prorok PC; Castle PE
J Natl Cancer Inst; 2023 Mar; 115(3):250-257. PubMed ID: 36458902
[TBL] [Abstract][Full Text] [Related]
8. New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
Hackshaw A; Clarke CA; Hartman AR
Cancer Cell; 2022 Feb; 40(2):109-113. PubMed ID: 35120599
[TBL] [Abstract][Full Text] [Related]
9. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.
Gelhorn H; Ross MM; Kansal AR; Fung ET; Seiden MV; Krucien N; Chung KC
Patient; 2023 Jan; 16(1):43-56. PubMed ID: 35844011
[TBL] [Abstract][Full Text] [Related]
10. Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives.
Loomans-Kropp HA; Umar A; Minasian LM; Pinsky PF
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):512-514. PubMed ID: 35253043
[TBL] [Abstract][Full Text] [Related]
11. Principles of Cancer Screening.
Pinsky PF
Surg Clin North Am; 2015 Oct; 95(5):953-66. PubMed ID: 26315516
[TBL] [Abstract][Full Text] [Related]
12. Screening for cancer: the economic, medical, and psychosocial issues.
Brill JV
Am J Manag Care; 2020 Nov; 26(14 Suppl):S300-S306. PubMed ID: 33200894
[TBL] [Abstract][Full Text] [Related]
13. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
Brito-Rocha T; Constâncio V; Henrique R; Jerónimo C
Cells; 2023 Mar; 12(6):. PubMed ID: 36980276
[TBL] [Abstract][Full Text] [Related]
14. Circulating cell-free DNA-based multi-cancer early detection.
Zhang K; Fu R; Liu R; Su Z
Trends Cancer; 2024 Feb; 10(2):161-174. PubMed ID: 37709615
[TBL] [Abstract][Full Text] [Related]
15. Modelled mortality benefits of multi-cancer early detection screening in England.
Sasieni P; Smittenaar R; Hubbell E; Broggio J; Neal RD; Swanton C
Br J Cancer; 2023 Jul; 129(1):72-80. PubMed ID: 37185463
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
17. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
18. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
[TBL] [Abstract][Full Text] [Related]
19. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Allele Fraction: A Candidate Biological Signal for Multicancer Early Detection Tests to Assess the Clinical Significance of Cancers.
Bredno J; Venn O; Chen X; Freese P; Ofman JJ
Am J Pathol; 2022 Oct; 192(10):1368-1378. PubMed ID: 35948080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
